Who is sponsoring NCT02899598?

NCT02899598 is sponsored by Assistance Publique Hopitaux De Marseille.

What drugs are being tested in NCT02899598?

Interventions in NCT02899598: Extra blood draw samples, extra amniotic fluid samples.

What condition does NCT02899598 study?

NCT02899598 studies Neonatal Thrombocytopenia Isoimmunization Maternal-fetal.

Is NCT02899598 still recruiting?

NCT02899598 is currently withdrawn. Last updated 28 July 2023.

Last reviewed 2023-07-28 · How we verify

NCT02899598

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Genotyping of Human Platelet Alloantigens : Non-invasive Prenatal Diagnosis

Withdrawn NA Last updated 28 July 2023

What this trial tests

NA trial testing Extra blood draw samples in Neonatal Thrombocytopenia Isoimmunization Maternal-fetal. Withdrawn.

Timeline

27 July 2023

Primary endpoint
27 July 2023

27 July 2023

Quick facts

Lead sponsor	Assistance Publique Hopitaux De Marseille
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Start date	27 July 2023
Primary completion	27 July 2023
Estimated completion	27 July 2023
Sites	1 location across France

Drugs / interventions tested

Extra blood draw samples — full drug profile →
extra amniotic fluid samples — full drug profile →

Conditions studied

Neonatal Thrombocytopenia Isoimmunization Maternal-fetal — all drugs for Neonatal Thrombocytopenia Isoimmunization Maternal-fetal →

Sponsor

Assistance Publique Hopitaux De Marseille — full company profile →

Who can join

18 and older, female only, with Neonatal Thrombocytopenia Isoimmunization Maternal-fetal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neonatal thrombocytopenia isoimmunization maternal-fetal is related to maternal immunization against fetal platelet antigens with paternal origin not present in the mother. It is considered the equivalent of hemolytic disease of the newborn. The incidence of this disease is about 1 in 800-1000 births. The most severe forms associated petechiae, purpura or cephalhematoma at birth with a major risk of cerebral hemorrhages (20% to 25% of cases) can cause the death of the child (15%) or severe neurological troubles (15-30%) Biologic diagnosis requires the detection of anti-platelet antibodies with maternal determination of platelet phenotypes and genotypes of the two parents. The objective of this work is to develop specific molecular tools to fetal platelet genotyping from maternal blood. We are particularly interested to antigens HPA-1, HPA-5 , HPA-3 and HPA-4. We evaluate the sensitivity and specificity of this test by comparing these results with those obtained from an invasive sampling of amniotic fluid. This is a prospective study to assess the technical and diagnostic performance of a new molecular method noninvasive prenatal diagnosis of platelet genotyping.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Extra blood draw samples

Trials testing the same drug.

NCT02904863 — Study of 'Vascular Competence' Profile and Endothelial Activation in the Hemolytic Uremic Syndrome in Children and Adult · NA · completed

Other Assistance Publique Hopitaux De Marseille trials

Trials by the same sponsor.

NCT07521644 — Dysbiosis of Methanogenic Archaea and Nanoarchaea in the Oral Microbiome · NA · not yet recruiting
NCT07357025 — Resting-State fMRI Study of Functional Connectivity After Gamma Knife Radiosurgery in Trigeminal Neuralgia · NA · not yet recruiting
NCT07356661 — Evaluation of the Efficacy of Neurofeedback Technique Based on EEG Desynchronization in Epileptic Patients · NA · not yet recruiting
NCT07399327 — Biomarkers of Response to SEEG Thermocoagulation · NA · not yet recruiting
NCT06999499 — Development of an Aid to Melanoma Detection Using Artificial Intelligence Algorithms Based on Images From the VECTRA 3D · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02899598 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique Hopitaux De Marseille
Last refreshed: 28 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02899598.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing